Source: Annual Congress 2009 - Continuous positive airway pressure therapy in obstructive sleep apnoea
Disease area: Sleep and breathing disorders



Rating:

Share or cite this content

Citations should be made in the following way:
P. Pinto, C. Barbara, S. Conde, C. Corrigan, A. S. Oliveira, R. Dias, C. Canhao, J. Teixeira, M. J. M. Gomes (Lisbon, Portugal). Catecholamines and obstructive sleep apnea (OSA) severity: response to positive airway pressure (PAP) therapy. Eur Respir J 2009; 34: Suppl. 53, 4548

Member's Comments

No comment yet.

Related content which might interest you: Adherence predictors to positive airway pressure (PAP) treatment in patients with obstructive sleep apnea (OSA) Source: Sleep and Breathing Conference 2021 Year: 2021 Adherence predictors to positive airway pressure (PAP) treatment in patients with obstructive sleep apnea (OSA). Source: Virtual Congress 2020 – Pathophysiology and treatment of obstructive sleep apnoea Year: 2020 Prediction of effective continuous positive airway pressure (CPAP) in obstructive sleep apnea syndrome (OSA) Source: Eur Respir J 2005; 26: Suppl. 49, 111s Year: 2005 Positional obstructive sleep apnea (OSA) and automatic positive airway pressure (APAP) therapy Source: Annual Congress 2012 - Technology, screening and questionnaires in OSA Year: 2012 Association between obstructive sleep apnea (OSA) and depression and the effect of continuous positive airway pressure (CPAP) treatment Source: Annual Congress 2012 - Clinical predictors of OSA, adherence to CPAP and psychology Year: 2012 Influence of nasal obstruction (NO) on obstructive sleep apnea (OSA) severity and continuous positive airway pressure (CPAP) adaptation problems Source: Annual Congress 2010 - The upper airway and oral appliances Year: 2010 Angiogenic factors in obstructive sleep apnea syndrome (OSA). Effects of nasal continuous positive airway pressure treatment (CPAP) Source: Annual Congress 2010 - Biomarkers for oxidative stress, inflammation and cardiovascular function in sleep apnoea Year: 2010 Prevalence and determinants of residual excessive daytime sleepiness (RES) in patients treated with continuous positive airway pressure (CPAP) for obstructive sleep apnea (OSA). Source: Virtual Congress 2020 – Advance in treatments for sleep and breathing disorders and long-term adherence Year: 2020 Effect of continuous positive airway pressure treatment (CPAP) in angiogenic growth factors‘ expression in patients with COPD and obstructive sleep apnea syndrome (OSAS) Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in chronic and acute airway diseases Year: 2010 Effects of continuous positive airway pressure (CPAP) on quality of life in patients with obstructive sleep apnea syndromes (OSAS) Source: Annual Congress 2010 - Clinical aspects of sleep apnoea Year: 2010 Prevalence and causes of residual sleepiness (RS) 12 months after continuous positive airway pressure (CPAP) treatment for obstructive sleep apnea syndome (OSAS) Source: Annual Congress 2010 - Sleep disorders: neurology, smoking and daytime sleepiness Year: 2010 Effect of automatic positive airway pressure (APAP) therapy on blood pressure (BP) in patients with obstructive sleep apnea (OSA) and hypertension Source: Annual Congress 2008 - Clinical aspects of continuous positive airway pressure therapy Year: 2008 Outcomes in patients with REM-related obstructive sleep apnoea (REM-OSA) treated with continuous positive airway pressure (CPAP) Source: International Congress 2019 – Treatment of continuous positive airway pressure and monitoring of its effects Year: 2019 Does positional apnea influence optimum continuous positive airway pressure (CPAP) in obstructive sleep apnea (OSA)? Source: Eur Respir J 2005; 26: Suppl. 49, 111s Year: 2005 Natural history of idiopathic pulmonary fibrosis (IPF) associated with obstructive sleep apnea (OSA) with or without continuous positive airway pressure (CPAP) Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias Year: 2018 Impact of humidification on compliance and side effects in obstructive sleep apnea (OSA) patients under auto continuous positive airway pressure (ACPAP) therapy Source: Eur Respir J 2006; 28: Suppl. 50, 409s Year: 2006 Plasma endothelin-1 (ET-1) levels in obstructive sleep apnea (OSA) patients and effect of continouous positive airway pressure (CPAP) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 40s Year: 2005 Effect of continuous positive airway pressure (CPAP) treatment on proangiogenic factors of angiogenesis in obstructive sleep apnea (OSA) patients Source: Eur Respir J 2005; 26: Suppl. 49, 39s Year: 2005 The influence of 3-weeks‘ therapy of continous positive airway pressure (CPAP) on serum leptin and homocysteine concentration in patients with obstructive sleep apnea (OSA) Source: Annual Congress 2005 - Metabolic control in OSA Year: 2005 Treatment of obstructive sleep apnoea with nasal continuous positive airway pressure in stroke Source: Eur Respir J 2001; 18: 623-629 Year: 2001